Musto, P., Salmanton‐García, J., Sgherza, N., Bergantim, R., Farina, F., Glenthøj, A. ... Pagano, L. (2023). Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the epicovideha registry. Hematological Oncology, 2023., 1-15. doi: 10.1002/hon.3240
Musto, Pellegrino, et al. "Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the epicovideha registry." Hematological Oncology, vol. 2023, 2023, str. 1-15. https://doi.org/10.1002/hon.3240
Musto, Pellegrino, Jon Salmanton‐García, Nicola Sgherza, Rui Bergantim, Francesca Farina, Andreas Glenthøj, Guldane Cengiz Seval, et al. "Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the epicovideha registry." Hematological Oncology 2023 (2023): 1-15. https://doi.org/10.1002/hon.3240
Musto, P., et al. (2023) 'Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the epicovideha registry', Hematological Oncology, 2023, str. 1-15. doi: 10.1002/hon.3240
Musto P, Salmanton‐García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, i sur.. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the epicovideha registry. Hematological Oncology [Internet]. 04.12.2023. [pristupljeno 04.12.2024.];2023:1-15. doi: 10.1002/hon.3240
P. Musto, et al., "Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the epicovideha registry", Hematological Oncology, vol. 2023, str. 1-15, Prosinac 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:174763. [Citirano: 04.12.2024.]